True Volume Depletion vs. Effective Arterial Blood Volume (EABV) Depletion

True hypovolemia occurs when total body water is reduced: hemorrhage, GI losses, renal losses (diuretics), insensible losses (fever, burns). Laboratory findings show BUN-to-Cr ratio >20:1, low urine sodium (<20 mEq/L), fractional excretion of sodium (FeNa) <1%, and concentrated urine (Uosm >600).

Effective arterial blood volume (EABV) depletion refers to the perception of reduced circulating volume by baroreceptors—not the total amount of body water. Classic examples: - Decompensated heart failure: total body water elevated, but cardiopulmonary baroreceptors sense underperfusion - Cirrhosis with ascites: massive third-spacing, renal sensors perceive hypovolemia despite hyperhydration - Nephrotic syndrome: severe hypoalbuminemia → reduced oncotic pressure → peripheral edema but EABV depletion

In all three states, the kidney responds by activating the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system, and antidiuretic hormone (ADH)—creating the classic pre-renal pattern: low FeNa, high BUN/Cr ratio, concentrated urine.

Why FeNa Is Low—But Treatment Is COMPLETELY Different

The mechanism of low FeNa unifies the pre-renal spectrum: 1. RAAS activation → increased angiotensin II → glomerular efferent arteriole vasoconstriction 2. Sympathetic stimulation → renal artery vasoconstriction + proximal tubule sodium reabsorption 3. ADH release → aquaporin-2 upregulation → water reabsorption + urine concentration 4. Aldosterone surge → sodium reabsorption in collecting duct 5. Result: Urine sodium <20 mEq/L, FeNa <1%, osmolality >600

But here’s the divergence: - True hypovolemia: Treatment = VOLUME restoration (IV fluids, transfusion, stopping diuretics) - Cardiorenal syndrome (HF): Treatment = DECONGESTIVE therapy (diuretics, vasodilators, inotropes, ultrafiltration) - Hepatorenal syndrome: Treatment = VASOCONSTRICTORS + albumin (NOT fluids—fluid worsens ascites and outcomes)

Giving IV fluids to a patient with decompensated heart failure and rising creatinine is harmful. Giving vasoconstrictors to a truly hypovolemic patient is dangerous. Yet all three present with low FeNa.

Ronco Classification (2008, Updated 2019)

Type 1 — Acute Cardiorenal Syndrome (Acute Decompensated Heart Failure → AKI)

Clinical presentation: Acute or sub-acute worsening of cardiac function → rapid rise in serum creatinine over hours to days. Classic scenario: acute pulmonary edema, hemodynamic instability (low BP, elevated filling pressures), rising Cr by ≥0.3 mg/dL.

Example: 68-year-old with ischemic cardiomyopathy (EF 25%) presents with dyspnea, orthopnea, BNP 1200. Baseline Cr 1.8. Initial labs: Cr 2.1, BUN 52, FeNa 0.8%. Physical exam shows JVD to 10 cm, bibasilar crackles, 3+ edema. This is Type 1 CRS.

Type 2 — Chronic Cardiorenal Syndrome (Chronic HF → Progressive CKD)

Chronic, progressive worsening of renal function over weeks to months secondary to chronic HF. The kidney is in a state of chronic underperfusion despite adequate systemic blood pressure. Often accompanied by RAAS upregulation, sympathetic hyperactivity, and progressive vascular stiffening.

Example: 72-year-old with diastolic HF (EF 50-55%), hypertension, diabetes presenting with NYHA Class III dyspnea. Baseline Cr was 1.2 two years ago; now 2.8. Echocardiogram shows restrictive pattern, elevated filling pressures. This is Type 2 CRS.

Type 3 — Renocardiac Syndrome (AKI → Cardiac Dysfunction)

Primary renal disease (AKI or CKD) → secondary cardiac decompensation. Mechanisms: volume overload, hypertension, anemia, hyperkalemia, uremia (myocardial stunning), hyperphosphatemia.

Example: 45-year-old with ANCA-associated vasculitis and rapidly progressive GN presents with Cr 6.2 (baseline 1.0), anemia (Hgb 7.2), K 6.1. Develops pulmonary edema and requires intubation. This is Type 3.

Type 4 — Secondary Cardiorenal Syndrome

Systemic disease affecting both organs: diabetes mellitus (far most common), sepsis, systemic sclerosis, systemic lupus erythematosus.

Type 5 — Tertiary (Acute Disease-Induced)

Acute systemic illness (infection, multi-organ failure) causing simultaneous cardiac and renal dysfunction.

Venous Congestion Hypothesis vs. Forward Flow Hypothesis

The traditional model blamed “forward flow” (reduced cardiac output → decreased renal perfusion). Modern physiology implicates venous congestion as the primary mechanism.

Venous Congestion Mechanism: - Elevated right atrial pressure → hepatic venous congestion → systemic venous hypertension - Elevated renal interstitial pressure and venous pressure reduce glomerular filtration pressure - Central venous pressure (CVP) >8–12 mmHg is associated with AKI progression - Elevated systemic venous pressure promotes sodium retention, worsens HF

Forward Flow Still Matters, But: - Mean arterial pressure >65 mmHg usually maintains adequate renal perfusion pressure - GFR can remain relatively preserved even with low cardiac output IF venous pressure is low - Conversely, high CVP can reduce GFR despite normal or high systemic BP

Clinical Integration: Both mechanisms contribute. Acute MI with cardiogenic shock has ischemic injury (poor forward flow) + venous congestion (backup to right heart). Chronic restrictive cardiomyopathy may have preserved systemic BP but persistently elevated CVP and progressive renal decline.

Central Venous Pressure and Its Impact on GFR

The glomerular filtration pressure (GFP) = Glomerular hydrostatic pressure − (Bowman’s capsule pressure + plasma oncotic pressure).

Under normal physiology, Bowman’s capsule pressure is ~10 mmHg. When CVP rises, Bowman’s capsule pressure rises in parallel, reducing GFP.

Empirical associations: - CVP <5 mmHg: usually associated with renal hypoperfusion - CVP 8–12 mmHg: “safe zone” for renal perfusion in most patients - CVP >15 mmHg: associated with AKI risk, especially if acute rise - Acute rise in CVP (e.g., 5 → 15 mmHg over hours) → rapid GFR fall

When Rising Creatinine in HF Is ACCEPTABLE: Pseudo-Worsening of Renal Function

One of the most misunderstood phenomena in cardiology and nephrology:

Definition: Rising serum creatinine (Cr) in the setting of decongestion (diuretics, vasodilators, ultrafiltration) despite improving clinical HF symptoms and hemodynamics.

Why It Happens: 1. Creatinine is filtered by the kidney and reabsorbed in the proximal tubule (20–30% reabsorbed) 2. During SEVERE volume depletion or low perfusion, proximal tubule reabsorption increases, RAISING serum Cr despite stable GFR 3. As diuretics improve HF and reduce CVP, GFR may actually IMPROVE, but creatinine-based estimates lag behind because: - Creatinine takes 24–48 hours to reach steady-state after GFR changes - Cystatin C (less tubular reabsorption) falls faster than creatinine during decongestion - Creatinine per se may briefly rise due to reduced renal perfusion during early diuresis, then stabilize or improve

Clinical Pattern: Patient receives aggressive diuretics (e.g., continuous furosemide infusion, ultrafiltration). Physical exam improves (less orthopnea, more urine output, BP normalizes). BNP falls. Echocardiogram shows improved EF. But creatinine rises from 1.8 → 2.2 over 48 hours.

Is this bad? NO—if other indicators of renal perfusion are good: - Urine output increasing (>0.5 mL/kg/h) - Urine is clearing (Uosm normalizing, FeNa may rise toward 1%) - Blood pressure stable or improving - Patient feels better, breathing improves

True worsening would be: - Continued oliguria despite diuretics (urine output <0.3 mL/kg/h) - Progressive hyperkalemia, metabolic acidosis - Symptoms of hypovolemia (orthostasis, decreased mentation, organ hypoperfusion) - Hemodynamic instability (SBP <90, end-organ hypoperfusion signs)

The Creatinine “Bump” During Decongestion: When to Continue vs. Stop Diuretics

The classic dilemma: Patient on furosemide infusion; creatinine rose 0.4 mg/dL in 24 hours. Attending says “stop the diuretics, we’re hurting the kidneys.” Cardiologist says “no, keep going, it’s pseudo-worsening.”

Decision framework:

The Furosemide Stress Test (FST) can help resolve this uncertainty — see detailed section below.

Furosemide Stress Test (FST): The Best Bedside Predictor of AKI Progression

Rationale: In acute decompensated HF with rising creatinine, we need to distinguish: - Pseudo-worsening (creatinine artifact; GFR stable) → safe to continue diuretics - Evolving ATN/intrinsic AKI → higher risk, consider ultrafiltration - Severe volume depletion/cardiogenic shock → diuretics harmful

Traditional markers (FeNa, BUN/Cr, muddy casts) are slow and insensitive. The FST offers real-time, direct measurement of renal response to diuretics.

Protocol:

For furosemide-naive patients: - Give 1.0 mg/kg IV push as single dose (e.g., 80 mg for 80 kg patient) - Collect urine for 2 hours - Measure total urine output

For patients on chronic loop diuretics: - Give 1.5 mg/kg IV push (e.g., 120 mg for 80 kg patient) to overcome refractoriness - Collect urine for 2 hours

Interpretation (2-hour urine volume): - >200 mL → “responder” → risk of KDIGO Stage 3 AKI is <5% → safe to continue diuretics - <200 mL → “non-responder” → risk of KDIGO Stage 3 AKI is 70–80% → consider ultrafiltration or more aggressive vasodilators

Evidence Quality:

Chawla et al. (2013) in Critical Care examined FST in 247 critically ill patients with AKI. AUC for predicting progression to Stage 3 AKI or death was 0.87—superior to: - RIFLE/AKIN staging alone (AUC 0.68) - Peak serum creatinine (AUC 0.71) - Urine biomarkers (NGAL, IL-18, KIM-1) - Cystatin C

Koyner et al. (2015) in J Am Soc Nephrol replicated findings in 200 patients; sensitivity 88%, specificity 86% for predicting Stage 3.

Matarrese et al. (2019) in heterogeneous ICU population: FST response accurately stratified mortality—non-responders had 3-fold higher 28-day mortality.

Continuous Furosemide Infusion

When Bolus Fails: Single-dose furosemide often fails to sustain diuresis in severe HF, especially in refractory cases. Continuous infusion maintains higher urinary furosemide concentration and prevents renal sodium avidity during the “rebound” phase between boluses.

Dosing: - Loading dose: 40 mg IV push (or 0.5 mg/kg if higher doses used recently) - Infusion: Start 5–10 mg/h; titrate by 5 mg/h every 2–4 hours based on urine output goal - Target: 200–400 mL/h urine output (typical range for decongestive therapy) - Maximum practical: 40–80 mg/h (higher rates offer marginal additional benefit)

Monitoring: - Hourly urine output (mandatory; watch for declining output = developing resistance) - Daily weights (goal: 1–2 lbs/day loss) - Twice-daily electrolytes (watch for hypokalemia, hyponatremia, metabolic alkalosis) - Daily creatinine (track curve; expect initial rise if pseudo-worsening, then plateau or fall) - Daily magnesium and calcium (losses can be severe with loop diuretics) - CVP/echocardiogram (assess filling pressures; goal CVP <8)

DOSE Trial Context (NEJM 2011): The DOSE trial (n=308) randomized acute HF patients to bolus vs. continuous furosemide and to low vs. high dosing. Primary outcome was symptom improvement; secondary was renal function.

• Continuous vs. bolus: no significant difference in symptom improvement or renal outcomes
• High-dose vs. low-dose: High-dose had better symptom relief but higher transient hearing loss (reversible)
• Conclusion: Both strategies work; choice depends on logistics. Continuous infusion preferred if:
  • Diuretic refractoriness develops
  • Need precise hourly titration
  • ICU setting with intensive monitoring

Dose Escalation and Resistance Mechanisms

Why HF patients become diuretic-resistant:

1. Reduced drug delivery: Splanchnic congestion → poor GI absorption (bolus PO); poor renal perfusion → low filtered load (even IV furosemide)
2. Enhanced tubular reabsorption: Activated RAAS, sympathetic nervous system, and ADH promote sodium reabsorption distal to loop of Henle
3. Pharmacokinetic tolerance: Prolonged furosemide use (>3 days continuous) may reduce renal furosemide secretion
4. Neurohormonal counter-regulation: RAAS surge overwhelms diuretic effect

Escalation Strategy: - Increase infusion rate incrementally (5–10 mg/h every 2–4 h) - Add metolazone (thiazide-like agent) to block distal tubule sodium reabsorption - Add acetazolamide (carbonic anhydrase inhibitor) to block proximal tubule sodium reabsorption - Add spironolactone (aldosterone antagonist) if K+ >3.5 and not in shock

Sequential Nephron Blockade and Combination Diuretic Therapy

The concept: Loop diuretics inhibit the Na-K-2Cl cotransporter in the thick ascending limb. But ~70% of filtered sodium is reabsorbed proximal to the loop and ~15% distal to the loop. Combining agents blocks multiple nephron segments.

Regimen 1: Furosemide + Metolazone - Most common combination for resistant HF edema - Furosemide: 40–80 mg/h continuous IV - Metolazone: 2.5–10 mg PO daily or BID (onset 1 h, peak 2–6 h) - Often produces dramatic diuresis (“synergistic effect”) - Watch for: severe hypokalemia (K+ drops 1–2 mEq/L/day), hyponatremia, acute renal worsening

Regimen 2: Furosemide + Acetazolamide - Acetazolamide: 250–500 mg IV/PO BID - Proximal tubule sodium and bicarbonate reabsorption blocker - Useful if metabolic alkalosis is severe (loop diuretics cause metabolic alkalosis; acetazolamide causes metabolic acidosis—they balance) - Caveat: Less potent than metolazone; often combined WITH metolazone in extreme resistance

Regimen 3: Furosemide + Spironolactone + Amiloride - Spironolactone: 12.5–25 mg daily (aldosterone antagonist; takes 3–5 days for effect) - Amiloride: 5–10 mg daily (potassium-sparing diuretic; direct ENaC blockade; faster onset) - Less powerful than metolazone but valuable for preventing hypokalemia - Use when K+ <3.5 or patient on ACEi/ARB (which raise K+)

Regimen 4: Extreme Resistance (ICU setting) - Furosemide infusion 40–80 mg/h - Metolazone 5 mg BID - Acetazolamide 500 mg IV BID - Thiamine + megadose MVI (diuretic losses huge) - Strongly consider ultrafiltration** if <500 mL urine output over 4–6 hours despite above

Aquapheresis / Ultrafiltration: When Diuretics Fail

Mechanism: Mechanical removal of isotonic fluid via convective flow; removes both solute and solvent (unlike osmotic or loop diuretics which remove water but RETAIN sodium in proximal diuretic-resistant cases).

When indicated: - Diuretic refractoriness (FST non-responder, urine <200 mL/2 h with maximal furosemide) - Severe hyponatremia (Na <125) unresponsive to fluid restriction + diuretics - Hypotension preventing further diuretics (ultrafiltration can improve BP by reducing afterload paradoxically) - Renal dysfunction (creatinine >2.5 and rising) with ongoing need for decongestion

Major trials:

UNLOAD (2007): Stepped care + ultrafiltration vs. IV diuretics in 200 acute HF patients. UF group had greater weight loss (5 kg vs. 3 kg) and fewer rehospitalizations at 6 months (4% vs. 25%, p<0.01). But inpatient mortality/renal function similar.

CARRESS-HF (2012): 188 patients with HF + AKI (Cr >1.5 or creatinine increase). Usual IV diuretics + protocol-driven management vs. stepped ultrafiltration. Diuretics won: UF did NOT improve renal function, did NOT reduce rehospitalization, and was more expensive. UF arm had higher adverse events (catheter infection, electrolyte abnormalities).

AVOID-HF (2018): Ultrafiltration vs. IV diuretics in acute HF. UF showed no benefit for symptoms, renal function, or readmission. Similar safety profile but higher costs.

SGLT2i in Acute Decompensated HF

Recent trials suggest SGLT2 inhibitors reduce HF readmission and may improve cardiorenal outcomes even acutely.

EMPULSE (2023): Empagliflozin in acute HF (n=530), double-blind. Primary outcome = cardiovascular death or hospitalization for HF at 25 days. - Empagliflozin group: primary outcome 25% vs. control 31% (p=0.027) - Early treatment (≤24 h of admission) showed strongest benefit - Improved dyspnea score, but no worsening of renal function or hypotension

Mechanism in AHF: - Direct tubular reabsorption of glucose/sodium (SGLT2 blockade) → improved natriuresis without hypokalemia - Improves myocardial energetics, reduces fibrosis - Reduces intrarenal pressure via afferent arteriolar dilation - Lowers uric acid (mild diuretic effect)

Tolvaptan in Hypervolemic Hyponatremia

Selective vasopressin V2-receptor antagonist. Used in acute decompensated HF with hyponatremia (Na <125) despite diuretics + fluid restriction.

Mechanism: Aquaresis (electrolyte-free water excretion) without sodium or potassium loss. Raises serum sodium without diuretic-induced electrolyte wasting.

Dosing: - Start 7.5 mg PO daily; titrate to max 15 mg daily - Requires hospitalization for first dose and osmolality monitoring - Monitor serum Na q4-6h initially; goal: raise Na 6–10 mEq/L per 24 h (faster increase risks osmotic demyelination)

Caveats: - Expensive (>$150–300/day) - Rebound hyponatremia common if stopped abruptly - Hyperkalemia risk (raises K by ~0.3 mEq/L; use carefully on ACEi/ARB) - Not first-line; reserve for symptomatic hyponatremia unresponsive to standard therapy

New ICA Nomenclature (2023): HRS-AKI and HRS-CKD

The International Club of Ascites (ICA) 2023 consensus abandoned the confusing Ronco nomenclature (Type 1 vs Type 2) in favor of:

HRS-AKI (formerly Type 1): Rapidly progressive renal failure in cirrhotic patient (Scr increase ≥50% from baseline within 2 weeks, or absolute increase ≥0.3 mg/dL within 48 h). High mortality (40–60% without treatment; ~10–15% with terlipressin + albumin).

HRS-CKD (formerly Type 2): Slowly progressive renal failure (GFR 20–40 mL/min, Cr 1.5–2.5). Associated with refractory ascites. Lower mortality than HRS-AKI but poor long-term prognosis without liver transplant (median survival 6–12 months if on treatment; weeks without).

Pathophysiology: Splanchnic Vasodilation → Renal Vasoconstriction

The modern integrated model of HRS:

1. Splanchnic vasodilation (from portal hypertension, bacterial endotoxin, NO overproduction, prostacyclin excess) → reduced systemic vascular resistance and arterial blood pressure
2. Baroreceptor sensing of hypotension → reflex activation of RAAS, sympathetic nervous system, ADH
3. Renal vasoconstriction (angiotensin II + norepinephrine + ADH) → reduced renal perfusion pressure and GFR
4. Renal sodium retention → ascites accumulation and hyponatremia
5. Progressive renal ischemia → if untreated, tubular necrosis and irreversible renal failure

Why true hypervolemia coexists with RAAS activation: - Kidneys perceive low “central blood volume” due to splanchnic pooling - RAAS activation causes sodium retention → ascites worsens → further splanchnic pooling - Net result: cirrhotic patient with massive ascites, edema, ELEVATED CVP, AND activated RAAS

Diagnostic Criteria (ICA 2023)

All must be present:

1. Cirrhosis with portal hypertension (clinical or imaging evidence)
2. Acute kidney injury per KDIGO criteria (increase in Scr ≥1.5× baseline within 1 week)
3. No improvement after albumin challenge (1 g/kg/day × 2 days; recheck Scr on day 3; if Scr not improved by ≥25%, HRS-AKI diagnosis confirmed)
4. No shock (MAP >65, no vasopressor dependence)
5. Absence of nephrotoxins: no ACEi/ARB use, NSAIDs, aminoglycosides, contrast in prior 1 week
6. Minimal proteinuria (<500 mg/day) and no hematuria on UA (argues against intrinsic kidney disease)
7. Renal ultrasound normal (rules out obstruction, chronic parenchymal disease)

Serum Creatinine Limitations in Cirrhosis

Serum creatinine is unreliable in cirrhosis because:

1. Reduced hepatic creatine synthesis → baseline Cr lower than muscle mass would predict
2. Reduced muscle mass (sarcopenia, malnutrition) → Cr does not reflect GFR well
3. Increased renal creatinine reabsorption (RAAS activation) → Cr rises slower despite falling GFR
4. Hyperbilirubinemia interferes with colorimetric Cr assays

Clinical consequence: A cirrhotic patient with Cr 1.2 may have GFR <30 mL/min. Conversely, Cr 1.2 → 1.5 may represent 50% GFR loss despite modest creatinine rise.

Better markers in cirrhosis: - Cystatin C (less affected by muscle mass; filters freely; not reabsorbed) - KDIGO stage using cystatin C (emerging consensus) - Urine neutrophil gelatinase-associated lipocalin (NGAL) (early marker of tubular injury) - FibroTest, FibroScan (assess degree of portal hypertension; worse fibrosis = higher HRS risk)

Treatment of HRS-AKI: Vasoconstrictors + Albumin

First-line: Terlipressin + Albumin

Terlipressin: Selective V1 vasopressin receptor agonist (constricts splanchnic and systemic vasculature). FDA approved in December 2022 (finally).

• Dosing: 0.4 mg IV bolus q4h; increase to 0.8 mg q4h if Scr not improving after 3 days
• Maximum: 1.2 mg/day divided into q4h dosing
• Albumin: 1 g/kg on day 1 (loading); then 0.5 g/kg on days 3, 5, 7, etc., or 25 g daily
• Duration: Continue terlipressin ≤14 days (beyond which tolerance develops or toxicity accumulates)

Evidence (CONFIRM Trial, 2023): - Terlipressin vs. placebo in HRS-AKI (n=300) - Primary outcome: Complete HRS reversal (Scr back to baseline ±0.3) within 14 days - Terlipressin: 29% vs. placebo 17% (p=0.036; NNT ~8) - Mortality benefit at 90 days: 32% vs. 40% (p=0.08, trend but not significant)

Caveat: CONFIRM enrolled carefully selected, hemodynamically stable patients. Real-world outcomes messier; NNT likely higher.

Side Effects of Terlipressin: - Respiratory failure / pulmonary edema (most common serious AE; 5–10% of patients) - Mechanism: vasconstriction increases afterload + fluid retention can precipitate decompensation - Watch for: worsening dyspnea, bilateral crackles, hypoxia - Management: reduce dose or stop; may need intubation + aggressive diuretics - Ischemic complications (digit ischemia, bowel ischemia, MI) — rare (<1%) but serious - Hypertension, headache, abdominal pain (common, usually tolerable) - Hyponatremia worsening (antidiuretic effect)

Alternative Vasoconstrictors: Midodrine + Octreotide, Norepinephrine

Midodrine + Octreotide (when terlipressin unavailable or not tolerated): - Midodrine: 7.5 mg PO TID (alpha-1 agonist; peripheral vasoconstriction) - Octreotide: 100 mcg SC/IV q8h (somatostatin analog; splanchnic vasodilation prevention) - Albumin: same as with terlipressin - Evidence: Retrospective studies show 50–60% response rate (similar to terlipressin in older trials) - Advantage: Oral midodrine usable in stable ward patients (terlipressin requires IV) - Disadvantage: Less potent than terlipressin; oral absorption variable in ascitic patients

Norepinephrine (ICU setting, hemodynamic monitoring): - Infusion 0.5–2 mcg/kg/min; titrate to MAP >70 - Rationale: More balanced vasoconstriction than pure alpha-1 agents; maintains renal perfusion pressure - Evidence: Small series show 40–60% HRS reversal; single-center trials only - Advantage: Can combine with inotropes (dobutamine) if cardiogenic component - Caution: Hyperglycemia, arrhythmia risk; requires ICU monitoring

TIPS as Rescue Therapy

Transjugular Intrahepatic Portosystemic Shunt: Radiologist-placed shunt between portal vein and hepatic vein, decompressing portal circulation.

When to consider: - HRS-AKI refractory to medical management (no Scr improvement after 7 days terlipressin + albumin) - HRS-CKD with refractory ascites limiting diuretics - Bridge to liver transplant in candidate patient

Outcomes: - HRS reversal: 40–70% of refractory cases - Problem: TIPS causes hepatic encephalopathy (portal blood now shunts systemically, bypassing hepatic detoxification) in 10–20% acutely, up to 30% chronically - Shunt thrombosis common (50% at 1 year; requires intervention) - Mortality benefit unproven in RCTs (mostly observational data)

Bottom line: TIPS is rescue therapy for transplant candidates with refractory HRS; not first-line.

Renal Outcomes and Mortality With and Without Liver Transplant

This is the critical section for prognostication.

HRS-AKI WITHOUT liver transplant candidacy (or no transplant available):

• With medical therapy (terlipressin + albumin): ~30% achieve Scr reversal to baseline. Of those, ~70% relapse within 2–4 weeks if terlipressin stopped
• Median transplant-free survival: 14–15 days on dialysis
• 6-month survival: 10–15% (abysmal)
• Off dialysis at discharge: ~9% recover spontaneously
• Reality: Most non-transplant candidates die within weeks of HRS diagnosis

HRS-AKI WITH liver transplant candidacy:

• Survival to transplant with KRT: 23–48% (better than expected given severity)
• Post-transplant renal recovery: ~75% recover renal function off dialysis within 6 months
• 1-year survival post-transplant: 80–85% (excellent, assuming graft success)
• Long-term renal survival: ~90% avoid CKD stage 4 at 5 years post-transplant

HRS-CKD (slowly progressive, Cr 1.5–2.5, refractory ascites):

• Without treatment: Median survival 6–12 months (better than HRS-AKI but poor)
• With terlipressin + albumin: ~60% response; median time to Scr reversal 21 days
• Off terlipressin: High relapse rate; requires long-term (unclear if >14 days) management
• Transplant outcomes: Similar to HRS-AKI if transplanted

Key figure from Allegretti & Solà-Esteve (Kidney Med 2020): - Non-transplant HRS-AKI cohort (n=100): median survival 6.8 days on vasoconstrictors - Transplant-listed cohort (n=100): median survival 36 days (5-fold difference due to transplant) - Post-transplant at 90 days: 81% alive

Step 1: Accurately Assess Volume Status

Hypovolemic (true volume depletion): - History: GI losses (vomiting, diarrhea, NG suction), renal losses (over-diuresis), insensible (fever, burns) - Exam: orthostasis, tachycardia, low JVD (<5 cm), dry mucous membranes, poor skin turgor, oliguria - Labs: BUN/Cr >20, FeNa <1%, Uosm >600, high-normal or elevated sodium - Treatment: IV fluids (isotonic crystalloid, 500 mL bolus; repeat q20 min x 3), then recheck vitals/urine

Euvolemic (acute kidney disease, prerenal from systemic disease): - History: sepsis, contrast exposure, medication-induced - Exam: normal JVD, normal BP, no edema, variable urine output - Labs: FeNa <1%, BUN/Cr >15, normal sodium, variable Uosm - Treatment: Support with judicious fluids (250 mL q1h if septic), hold diuretics

Hypervolemic (HF, cirrhosis, nephrotic syndrome): - History: orthopnea, dyspnea, weight gain, ascites, leg edema - Exam: elevated JVD (>8 cm), basilar crackles, edema (dependent or anasarca), hepatomegaly/ascites - Labs: FeNa <1%, BUN/Cr normal or only mildly elevated, low-normal or low sodium - Treatment: DEPENDS on underlying cause — see below

Step 2: Determine Underlying Cause & Select Therapy

Flowchart:

AKI with low FeNa
│
├─ Hypovolemic exam + history?
│  └─→ YES: IV FLUIDS (hold diuretics)
│       Monitor Cr/urine q2-4h
│       If Cr not improving in 6h, recheck volume status
│
├─ Euvolemic + sepsis/contrast/drugs?
│  └─→ YES: SUPPORTIVE CARE (fluids for sepsis, hold nephrotoxins)
│       Discontinue ACEi/ARB/NSAIDs
│       Maintain MAP >65
│
└─ Hypervolemic exam (elevated JVD, crackles, edema)?
   │
   ├─ Heart failure (low EF or diastolic dysfunction)?
   │  └─→ YES: CARDIORENAL SYNDROME (see 5.3 below)
   │
   ├─ Cirrhosis (jaundice, spider angioma, caput medusae)?
   │  └─→ YES: HEPATORENAL SYNDROME (see 5.4 below)
   │
   └─ Nephrotic (urine protein >3.5, hypoalbuminemia)?
       └─→ YES: Volume EXPANSION initially if symptomatic
           (paradoxically helps renal perfusion despite EABV depletion)
           Diuretics AFTER albumin repletion + salt restriction

Cardiorenal Syndrome Algorithm (Figure 5.1)

Step 1: Confirm HF physiology - Echocardiogram: EF, filling pattern, chamber size, diastolic dysfunction - BNP/NT-proBNP: >400 diagnostic (see BNP interpretation section) - Exam: JVD, crackles, edema, orthopnea, paroxysmal nocturnal dyspnea (PND)

Step 2: Assess renal perfusion urgency - If SBP <90 AND no urine output → CARDIOGENIC SHOCK → ICU, consider inotropes (dobutamine, milrinone) + invasive hemodynamics - If SBP 90–100 + adequate urine → proceed to Step 3 - If SBP >100 → low-risk; can use aggressive diuretics

Step 3: Assess diuretic response - If responsive to IV furosemide (urine >500 mL in 2 h) → continue IV furosemide ± vasodilators (nitroprusside, nitroglycerin) - If inadequate response → perform FST - FST responder (>200 mL/2 h) → continue diuretics - FST non-responder (<200 mL/2 h) → switch to ultrafiltration or continuous furosemide + metolazone

Step 4: Address underlying etiology - Acute MI → revascularization (PCI/CABG) - Acute valvular disease → surgical consultation - Myocarditis → supportive care, consider ECMO if cardiogenic shock - Uncontrolled hypertension → aggressive BP control (goal MAP >85 but <110) - Uncontrolled arrhythmia (AFib, VT) → rate control or cardioversion

Step 5: Monitor for pseudo-worsening - Daily Cr, BUN, electrolytes (K, Mg, Ca), urine output - If Cr rises 0.3–0.5 mg/dL but CVP improving, urine output >200 mL/h, BP stable → CONTINUE diuretics - If Cr rises >0.5 mg/dL AND oliguria or symptoms of hypovolemia → SLOW diuretic rate; assess for cardiogenic shock

Hepatorenal Syndrome Algorithm (Figure 5.2)

Step 1: Confirm cirrhosis + portal hypertension - Imaging (ultrasound, CT, MRI): liver echotexture, ascites, varices, portal vein thrombosis - Labs: INR >1.5, low albumin, thrombocytopenia, hyperbilirubinemia, low sodium

Step 2: Rule out alternative causes of AKI in cirrhotic - Albumin challenge (mandatory): 1 g/kg IV daily × 2 days - Recheck Scr on day 3 - If Scr improved ≥25%, likely hypovolemia not HRS → continue albumin, hold diuretics - If Scr not improved, proceed to Step 3

• Exclude nephrotoxins: recent ACEi/ARB, NSAIDs, aminoglycosides, contrast
• Exclude acute tubular necrosis: ask about hypotension episode, sepsis, transfusion reaction
• Renal ultrasound: rule out hydronephrosis, chronic parenchymal disease, thrombosis

Step 3: Confirm HRS-AKI or HRS-CKD diagnosis (see ICA 2023 criteria above)

Step 4: Initiate vasoconstrictor + albumin - Terlipressin (preferred): 0.4 mg IV q4h; can increase to 0.8 mg q4h after 3 days if Scr not improving - Plus albumin: 1 g/kg day 1 (loading); then 0.5 g/kg days 3, 5, 7, etc. - Alternative if terlipressin unavailable: midodrine 7.5 mg PO TID + octreotide 100 mcg SC/IV q8h + albumin - Duration: Continue ≤14 days (tolerance develops; toxicity accumulates)

Step 5: Assess transplant candidacy - CRITICAL: If transplant candidate (age <70, no malignancy, reasonable cardiac function), intensify management and ICU admission - If non-candidate: shared decision-making regarding code status, ICU admission, dialysis

Step 6: Respond to therapy or escalate - Day 3: Check Scr; if improved ≥25%, continue vasoconstrictors - Day 7: If Scr not improved, consider TIPS (if transplant candidate and interventional radiology available) - Day 14: If no response, stop vasoconstrictors (toxicity outweighs benefit); focus on comfort care (if non-candidate) or bridge to transplant (if candidate)

Consultation Strategy